Gene therapy news - the latest biotech news from Labiotech.eu

Home Gene therapy Page 22

Latest Posts

Cell and Gene Therapies Europe

Interview 18 Apr 2018

What Lies Ahead for European Cell and Gene Therapies?

Cell and gene therapies have recently made big advances in providing effective treatments for a variety of conditions, from cancers to rare diseases. Nonetheless, there are still significant challenges ahead before the technologies can become a viable treatment option for most patients. What if you could treat a disease on the level of tissue and […]

April 18, 2018 - 5 minutesmins - By Alexander Burik

gene sequencing Gio.tto fi

News and Trends 17 Apr 2018

How Low Can the Price of a Next Generation DNA Sequencer Go?

The next generation of DNA sequencers has arrived, and with it, a clash of titans: Illumina, Thermo Fisher and Qiagen are all competing for the clinical diagnostics market. Next-generation sequencing (NGS) companies are redefining DNA sequencing. What began as small-scale PCR and Sanger sequencing efforts have now mushroomed into a $20Bn market with broad medical implications for […]

April 17, 2018 - 5 minutesmins - By External Contributor

genesight gene therapy blindness placebo

News and Trends 4 Apr 2018

Placebo Beats a Gene Therapy for Blindness in a Phase 3 Trial

GenSight has demonstrated that its gene therapy for a rare disease causing blindness can significantly improve the vision of patients. But so does the placebo. GenSight Biologics has released the results of a Phase III clinical trial testing its gene therapy GS010 in patients suffering from Leber hereditary optic neuropathy (LHON), a rare mitochondrial disease […]

April 4, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

cell and gene therapy

Interview 20 Mar 2018

Why It’s the Best Time to Be in Cell and Gene Therapy

Cell and gene therapies are here, and they’re here to stay. We stopped to chat about the future of the field with Alexander Vos last week at Bio Europe Spring. The cell and gene therapy space has been given a big boost in the last couple of years. Since 2016, GSK’s gene therapy Strimvelis is available […]

March 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

shutterstock 407422783

News and Trends 6 Mar 2018

Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III Trial

Nightstar Therapeutics will begin the first Phase III trial for a gene therapy targeting choroideremia, a rare disorder leading to complete blindness. Nightstar will launch the first-ever Phase III trial testing a gene therapy for choroideremia, a genetic disorder characterized by night blindness and gradual loss of vision that eventually leads to complete blindness. The trial, STAR, […]

March 6, 2018 - 2 minutesmins - By Alexander Burik

vision loss gene therapy gensight3 1

News and Trends 20 Feb 2018

This Gene Therapy for Vision Loss is Safe and Effective After Two Years

The results of a long-term follow-up suggest that GenSight’s gene therapy for Leber hereditary optic neuropathy can provide safe and effective treatment for the genetic cause of vision loss. GenSight develops gene therapies to preserve or restore vision in patients with neurodegenerative diseases of the retina. The biotech’s lead candidate is GS010, which is currently […]

February 20, 2018 - 3 minutesmins - By Alex Dale

ADVERTISEMENT

gene synthesis synbio Evonetix 1

News and Trends 31 Jan 2018

Gene Synthesizing Biotech Gets $12M to Boost the Synbio Field

Evonetix has closed a Series A fundraising round to support the development of its gene synthesis platform, an important tool in the emerging synbio field. Evonetix, based in Cambridge, UK, is developing a scalable, high fidelity gene synthesis approach that could be a key tool in the growing synbio field. The biotech has closed a […]

January 31, 2018 - 3 minutesmins - By Alex Dale

gmo gene editing europe2 1

In Depth 31 Jan 2018

Why Does Europe Lag Behind the US and China in the Gene Editing Race?

America and China lead the development of new gene editing technologies, producing GMOs and bringing CRISPR-based therapies into the clinic. Could this render European biotechs in this area obsolete? Gene editing technologies have revolutionized genetics and mark a new generation in biomedical and agricultural sciences. There are endless applications for the technology, including gene therapies for […]

January 31, 2018 - 6 minutesmins - By Ekaterina Perets

MinIOn 3 0 e1480700035353

News and Trends 30 Jan 2018

Update: Pocket Device makes its Debut in Whole Human Genome Sequencing

Update (30/01/2018): Oxford Nanopore has published a study in Nature Biotechnology outlining the first use of its pocket MinION device to sequence a human genome. The device was able to read sequences of DNA that are “hundreds of times larger than usual,” helping scientists better reconstruct the whole genome sequence. MinION costs less than $1,000 and […]

January 30, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

dante labs 10000 genomes project 1

News and Trends 29 Jan 2018

This Italian Biotech Will Sequence 10,000 Genomes in 2 Years

Dante Labs will use its DNA testing kit to sequence the DNA of 10,000 Europeans in an effort to improve our understanding of the human genome. Dante Labs developed the first DNA test to be made available in Europe, allowing the public to test their health from the comfort of their own homes. It has now […]

January 29, 2018 - 2 minutesmins - By Alex Dale

luxturna rights novartis deal1

News and Trends 25 Jan 2018

Novartis Will Bring US Gene Therapy for Blindness to Europe

The Swiss pharma has bought into the gene editing therapy game in a deal with Spark worth $170M (€137M) for commercialization rights outside the US. Novartis first marked out its position as a gene therapy leader in 2012 when it threw its hat into the CAR-T ring. Just a few months after the FDA approved […]

January 25, 2018 - 2 minutesmins - By Evelyn Warner

gensight retinitis pigmentosa gene therapy

News and Trends 10 Jan 2018

French Biotech Starts Trials to Restore Sight in All Types of Retinitis Pigmentosa

GenSight will start a clinical trial in the UK testing a combination of gene therapy and a wearable device to restore sight in patients with retinitis pigmentosa. The UK Medicines and Healthcare Regulatory Agency (MHRA) has accepted GenSight’s application to run a first clinical trial in the UK testing a new type of therapy with the […]

January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT